TY - JOUR
T1 - Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI)
AU - Leruez-Ville, Marianne
AU - Chatzakis, Christos
AU - Lilleri, Daniele
AU - Blazquez-Gamero, Daniel
AU - Alarcon, Ana
AU - Bourgon, Nicolas
AU - Foulon, Ina
AU - Fourgeaud, Jacques
AU - Gonce, Anna
AU - Jones, Christine E.
AU - Klapper, Paul
AU - Krom, André
AU - Lazzarotto, Tiziana
AU - Lyall, Hermione
AU - Paixao, Paulo
AU - Papaevangelou, Vassiliki
AU - Puchhammer, Elisabeth
AU - Sourvinos, George
AU - Vallely, Pamela
AU - Ville, Yves
AU - Vossen, Ann
PY - 2024/5
Y1 - 2024/5
N2 - Congenital cytomegalovirus (cCMV) infection carries a significant burden with a 0.64% global prevalence and a 17–20% chance of serious long-term effects in children. Since the last guidelines, our understanding, particularly regarding primary maternal infections, has improved. A cCMV guidelines group was convened under the patronage of the European Society of Clinical Virology in April 2023 to refine these insights. The quality and validity of selected studies were assessed for potential biases and the GRADE framework was employed to evaluate quality of evidence across key domains. The resulting recommendations address managing cCMV, spanning prevention to postnatal care. Emphasizing early and accurate maternal diagnosis through serological tests enhances risk management and prevention strategies, including using valaciclovir to prevent vertical transmission. The guidelines also strive to refine personalized postnatal care based on risk assessments, ensuring targeted interventions for affected families.
AB - Congenital cytomegalovirus (cCMV) infection carries a significant burden with a 0.64% global prevalence and a 17–20% chance of serious long-term effects in children. Since the last guidelines, our understanding, particularly regarding primary maternal infections, has improved. A cCMV guidelines group was convened under the patronage of the European Society of Clinical Virology in April 2023 to refine these insights. The quality and validity of selected studies were assessed for potential biases and the GRADE framework was employed to evaluate quality of evidence across key domains. The resulting recommendations address managing cCMV, spanning prevention to postnatal care. Emphasizing early and accurate maternal diagnosis through serological tests enhances risk management and prevention strategies, including using valaciclovir to prevent vertical transmission. The guidelines also strive to refine personalized postnatal care based on risk assessments, ensuring targeted interventions for affected families.
KW - Congenital cytomegalovirus infection
KW - Guidelines
KW - Neonatal
KW - Postnatal
KW - Prenatal
UR - http://www.scopus.com/inward/record.url?scp=85189468746&partnerID=8YFLogxK
U2 - 10.1016/j.lanepe.2024.100892
DO - 10.1016/j.lanepe.2024.100892
M3 - Review article
C2 - 38590940
AN - SCOPUS:85189468746
SN - 2666-7762
VL - 40
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
M1 - 100892
ER -